ADMA predicts major adverse renal events in patients with mild renal impairment and/or diabetes mellitus undergoing coronary angiography

Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of the nitric oxide (NO)-synthase and a biomarker of endothelial dysfunction (ED). ED plays an important role in the pathogenesis of contrast-induced nephropathy (CIN). The aim of our study was to evaluate serum ADMA concentration as a bi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Medicine (Baltimore)
Main Authors: Heunisch, Fabian, Chaykovska, Lyubov, von Einem, Gina, Alter, Markus, Dschietzig, Thomas, Kretschmer, Axel, Kellner, Karl-Heinz, Hocher, Berthold
Formato: Artigo
Idioma:Inglês
Publicado em: Wolters Kluwer Health 2017
Assuntos:
5200
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5313016/
https://ncbi.nlm.nih.gov/pubmed/28178159
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000006065
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados